First Header Logo Second Header Logo

Connection

John Parks to Phosphatidylcholine-Sterol O-Acyltransferase

This is a "connection" page, showing publications John Parks has written about Phosphatidylcholine-Sterol O-Acyltransferase.
  1. Lee JY, Badeau RM, Mulya A, Boudyguina E, Gebre AK, Smith TL, Parks JS. Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice. J Lipid Res. 2007 May; 48(5):1052-61.
    View in: PubMed
    Score: 0.283
  2. Zhao Y, Thorngate FE, Weisgraber KH, Williams DL, Parks JS. Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry. 2005 Jan 25; 44(3):1013-25.
    View in: PubMed
    Score: 0.246
  3. Zhao Y, Gebre AK, Parks JS. Amino acids 149 and 294 of human lecithin:cholesterol acyltransferase affect fatty acyl specificity. J Lipid Res. 2004 Dec; 45(12):2310-6.
    View in: PubMed
    Score: 0.240
  4. Zhao Y, Wang J, Gebre AK, Chisholm JW, Parks JS. Negative charge at amino acid 149 is the molecular determinant for substrate specificity of lecithin: cholesterol acyltransferase for phosphatidylcholine containing 20-carbon sn-2 fatty acyl chains. Biochemistry. 2003 Dec 02; 42(47):13941-9.
    View in: PubMed
    Score: 0.227
  5. Furbee JW, Parks JS. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis. 2002 Nov; 165(1):89-100.
    View in: PubMed
    Score: 0.211
  6. Furbee JW, Francone O, Parks JS. In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice. J Lipid Res. 2002 Mar; 43(3):428-37.
    View in: PubMed
    Score: 0.201
  7. Furbee JW, Sawyer JK, Parks JS. Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem. 2002 Feb 01; 277(5):3511-9.
    View in: PubMed
    Score: 0.197
  8. Furbee JW, Francone O, Parks JS. Alteration of plasma HDL cholesteryl ester composition with transgenic expression of a point mutation (E149A) of human LCAT. J Lipid Res. 2001 Oct; 42(10):1626-35.
    View in: PubMed
    Score: 0.196
  9. Parks JS, Huggins KW, Gebre AK, Burleson ER. Phosphatidylcholine fluidity and structure affect lecithin:cholesterol acyltransferase activity. J Lipid Res. 2000 Apr; 41(4):546-53.
    View in: PubMed
    Score: 0.176
  10. Chisholm JW, Gebre AK, Parks JS. Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase. J Lipid Res. 1999 Aug; 40(8):1512-9.
    View in: PubMed
    Score: 0.168
  11. Parks JS, Gebre AK, Furbee JW. Lecithin-cholesterol acyltransferase. Assay of cholesterol esterification and phospholipase A2 activities. Methods Mol Biol. 1999; 109:123-31.
    View in: PubMed
    Score: 0.162
  12. Huggins KW, Curtiss LK, Gebre AK, Parks JS. Effect of long chain polyunsaturated fatty acids in the sn-2 position of phosphatidylcholine on the interaction with recombinant high density lipoprotein apolipoprotein A-I. J Lipid Res. 1998 Dec; 39(12):2423-31.
    View in: PubMed
    Score: 0.161
  13. Wang J, DeLozier JA, Gebre AK, Dolphin PJ, Parks JS. Role of glutamic acid residues 154, 155, and 165 of lecithin:cholesterol acyltransferase in cholesterol esterification and phospholipase A2 activities. J Lipid Res. 1998 Jan; 39(1):51-8.
    View in: PubMed
    Score: 0.151
  14. Wang J, Gebre AK, Anderson RA, Parks JS. Cloning and in vitro expression of rat lecithin:cholesterol acyltransferase. Biochim Biophys Acta. 1997 Jun 23; 1346(3):207-11.
    View in: PubMed
    Score: 0.145
  15. Miller KR, Parks JS. Influence of vesicle surface composition on the interfacial binding of lecithin:cholesterol acyltransferase and apolipoprotein A-I. J Lipid Res. 1997 Jun; 38(6):1094-102.
    View in: PubMed
    Score: 0.145
  16. Parks JS, Gebre AK. Long-chain polyunsaturated fatty acids in the sn-2 position of phosphatidylcholine decrease the stability of recombinant high density lipoprotein apolipoprotein A-I and the activation energy of the lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1997 Feb; 38(2):266-75.
    View in: PubMed
    Score: 0.142
  17. Wang J, Gebre AK, Anderson RA, Parks JS. Amino acid residue 149 of lecithin:cholesterol acyltransferase determines phospholipase A2 and transacylase fatty acyl specificity. J Biol Chem. 1997 Jan 03; 272(1):280-6.
    View in: PubMed
    Score: 0.141
  18. Miller KR, Wang J, Sorci-Thomas M, Anderson RA, Parks JS. Glycosylation structure and enzyme activity of lecithin:cholesterol acyltransferase from human plasma, HepG2 cells, and baculoviral and Chinese hamster ovary cell expression systems. J Lipid Res. 1996 Mar; 37(3):551-61.
    View in: PubMed
    Score: 0.133
  19. Gu X, Wu Z, Huang Y, Wagner MA, Baleanu-Gogonea C, Mehl RA, Buffa JA, DiDonato AJ, Hazen LB, Fox PL, Gogonea V, Parks JS, DiDonato JA, Hazen SL. A Systematic Investigation of Structure/Function Requirements for the Apolipoprotein A-I/Lecithin Cholesterol Acyltransferase Interaction Loop of High-density Lipoprotein. J Biol Chem. 2016 Mar 18; 291(12):6386-95.
    View in: PubMed
    Score: 0.132
  20. Parks JS, Li H, Gebre AK, Smith TL, Maeda N. Effect of apolipoprotein A-I deficiency on lecithin:cholesterol acyltransferase activation in mouse plasma. J Lipid Res. 1995 Feb; 36(2):349-55.
    View in: PubMed
    Score: 0.123
  21. Liu M, Seo J, Allegood J, Bi X, Zhu X, Boudyguina E, Gebre AK, Avni D, Shah D, Sorci-Thomas MG, Thomas MJ, Shelness GS, Spiegel S, Parks JS. Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. J Biol Chem. 2014 Jan 31; 289(5):2801-14.
    View in: PubMed
    Score: 0.114
  22. Parks JS, Thuren TY, Schmitt JD. Inhibition of lecithin:cholesterol acyltransferase activity by synthetic phosphatidylcholine species containing eicosapentaenoic acid or docosahexaenoic acid in the sn-2 position. J Lipid Res. 1992 Jun; 33(6):879-87.
    View in: PubMed
    Score: 0.102
  23. Ettinger WH, Miller LD, Albers JJ, Smith TK, Parks JS. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res. 1990 Jun; 31(6):1099-107.
    View in: PubMed
    Score: 0.089
  24. Parks JS, Bullock BC, Rudel LL. The reactivity of plasma phospholipids with lecithin:cholesterol acyltransferase is decreased in fish oil-fed monkeys. J Biol Chem. 1989 Feb 15; 264(5):2545-51.
    View in: PubMed
    Score: 0.082
  25. Hirsch-Reinshagen V, Donkin J, Stukas S, Chan J, Wilkinson A, Fan J, Parks JS, Kuivenhoven JA, Lütjohann D, Pritchard H, Wellington CL. LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins. J Lipid Res. 2009 May; 50(5):885-93.
    View in: PubMed
    Score: 0.080
  26. Lee JY, Timmins JM, Mulya A, Smith TL, Zhu Y, Rubin EM, Chisholm JW, Colvin PL, Parks JS. HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney. J Lipid Res. 2005 Oct; 46(10):2233-45.
    View in: PubMed
    Score: 0.064
  27. Lee RG, Shah R, Sawyer JK, Hamilton RL, Parks JS, Rudel LL. ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J Lipid Res. 2005 Jun; 46(6):1205-12.
    View in: PubMed
    Score: 0.062
  28. Lee RG, Kelley KL, Sawyer JK, Farese RV, Parks JS, Rudel LL. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res. 2004 Nov 12; 95(10):998-1004.
    View in: PubMed
    Score: 0.060
  29. Temel RE, Parks JS, Williams DL. Enhancement of scavenger receptor class B type I-mediated selective cholesteryl ester uptake from apoA-I(-/-) high density lipoprotein (HDL) by apolipoprotein A-I requires HDL reorganization by lecithin cholesterol acyltransferase. J Biol Chem. 2003 Feb 14; 278(7):4792-9.
    View in: PubMed
    Score: 0.053
  30. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. J Biol Chem. 1997 Mar 14; 272(11):7278-84.
    View in: PubMed
    Score: 0.036
  31. Thornburg JT, Parks JS, Rudel LL. Dietary fatty acid modification of HDL phospholipid molecular species alters lecithin: cholesterol acyltransferase reactivity in cynomolgus monkeys. J Lipid Res. 1995 Feb; 36(2):277-89.
    View in: PubMed
    Score: 0.031
  32. Wu Z, Wagner MA, Zheng L, Parks JS, Shy JM, Smith JD, Gogonea V, Hazen SL. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol. 2007 Sep; 14(9):861-8.
    View in: PubMed
    Score: 0.018
  33. Babiak J, Tamachi H, Johnson FL, Parks JS, Rudel LL. Lecithin:cholesterol acyltransferase-induced modifications of liver perfusate discoidal high density lipoproteins from African green monkeys. J Lipid Res. 1986 Dec; 27(12):1304-17.
    View in: PubMed
    Score: 0.017
  34. Sorci-Thomas MG, Parks JS, Kearns MW, Pate GN, Zhang C, Thomas MJ. High level secretion of wild-type and mutant forms of human proapoA-I using baculovirus-mediated Sf-9 cell expression. J Lipid Res. 1996 Mar; 37(3):673-83.
    View in: PubMed
    Score: 0.008
  35. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, Verdery RB. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb. 1994 Jan; 14(1):8-13.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.